Research Article

EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON FASTING BLOOD GLUCOSE IN PROSTATE CANCER PATIENTS AT A TEACHING HOSPITAL IN SOUTHWESTERN NIGERIA - A PILOT STUDY

Daluchukwu J. Obi1*, Chiamaka Ehiedu1, Abbas A Abdus-Salam2, Atara I Ntekim2, Augustine Takure3, Ifeanyichukwu Nwanji4, Olumide Farinre5, Adeniyi Adenipekun2
1 Department of Radiation Oncology, University College Hospital, Ibadan PMB 5116, Nigeria.
2 Radiation Oncology Department, University College Hospital, Ibadan, Oyo State, Nigeria
3 Department of Urology, University of Ibadan and University College Hospital, Ibadan PMB 5116, Nigeria.
4 Department of Pathology, University of Ibadan and University College Hospital, Ibadan PMB 5116, Nigeria
5 Department of Urology, University College Hospital, Ibadan PMB 5116, Nigeria.
* Corresponding author: dalujobi@gmail.com
Published: Jul, 2025
DOI: 10.67579/njo.2025.z2hnreiu
Pages: 289-299
Views: 261
Downloads: 139

Abstract

Background: Prostate cancer is the most common cancer and the leading cause of cancer death in Nigerian men. There are many modalities of treatment of prostate cancer, among them is hormonal treatment with the use of androgen-deprivation therapy (ADT), and this has been reported to have effects on the blood glucose level, causing hyperglycaemia.


Objective: To determine the effects of three-month administration of ADT on fasting blood glucose in prostate cancer patients.


Methods: This prospective pilot study involved 15 histologically diagnosed prostate cancer patients who were not diabetic. Baseline measurements of fasting blood glucose were done before the commencement of ADT. Follow-up assessments occurred after 3 months of ADT administration. Data was analysed using logistic regression.


Result: Fifteen patients who met the study’s selection criteria were recruited. The age of the patients ranged from 56 to 88 years, with a median age of 70 years. There was a 5.8% increase in the mean FBS from 95.1mg/dl (±11.2mg/dl) at baseline to 100.6mg/dl (±11.8mg/dl) at 3 months (p=0.171). Subgroup analysis revealed a statistically significant 6.1% increase in the median FBS from 90.0mg/dl (range: 80 – 114mg/dl) at baseline to 95.5mg/dl (range:88 – 119mg/dl) at 3 months (p=0.027) among patients with hypertension, however, the increase in the mean was not statistically significant (p=0.09).


Conclusion: This pilot study suggested that ADT therapy may not be associated with hyperglycaemia after 3 months. Further research will further provide insight into the risks associated with men on ADT developing hyperglycaemia and the timing of these metabolic changes in the course of their treatment. This will help in the early identification and management of this complication.


Keywords

ADT Prostate cancer hyperglycaemia fasting blood glucose

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
  2. Cancer Today [Internet]. [cited 2025 Apr 4]. Available from: https://gco.iarc.fr/today/fact-sheets-cancer/about
  3. Naifar M, Rekik N, Messedi M, Chaabouni K, Lahiani A, Turki M, et al. Male hypogonadism and metabolic syndrome. Andrologia. 2015;47(5):579-86.
  4. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979-83.
  5. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl. 2008;29(5):534–9.
  6. Mean fasting blood glucose [Internet]. [cited 2025 Apr 2]. Available from: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380
  7. Bassey IE, Usoro CAO, Esiere KSU. Effect of Androgen Deprivation Therapy on Indices of Glycaemia and Insulin Resistance in Native African Prostate Cancer Patients. J Neoplasm. 2017;2(2):10.
  8. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.
  9. Sağlam HS, Köse O, Kumsar S, Budak S, Adsan O. Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. ScientificWorldJournal. 2012;2012:696329.
  10. Wong CHM, Xu N, Lim J, Feng KK, Chan WKW, Chan MTY, et al. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study. Prostate. 2023;83(8):801-808.
  11. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581-8.
  12. Irawan W, Warli SM. The effect of androgen deprivation therapy on the lipid profile and blood glucose level in prostate cancer patients in Adam Malik General Hospital, Medan. Indonesian Journal of Urology. 2017;24(2):93-96
  13. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2006; discussion 2007.
  14. Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):224–32.
  15. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40(1):189-207.
  16. Yu I-C, Lin H-Y, Sparks JD, Yeh S, Chang C. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes. 2014;63(10):3180–8.
  17. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004;13(1):47–55.
  18. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol. 2014;6(7):517–30.
  19. Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, et al. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses. Arterioscler Thromb Vasc Biol. 2020;40(3):e55-e64.
  20. Ng CF, Chiu PKF, Yee CH, Lau BSY, Leung SCH, Teoh JYC. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. Sci Rep. 2020;10(1):18060.
  21. Chen Y, Lin P-H, Freedland SJ, Chi J-T. Metabolic response to androgen deprivation therapy of prostate cancer. Cancers (Basel). 2024;16(11).
  22. Mohamedali HZ, Alibhai SM. Does androgen deprivation therapy increase diabetes risk? Diabetes Management. 2011;1(6):551–3.
  23. Mohamedali HZ, Breunis H, Timilshina N, Alibhai SMH. Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J. 2011;5(1):28–32.
  24. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176(2):520-5.
How to Cite

Obi, D. J., Ehiedu, C., Abdus-Salam, A. A., Ntekim, A. I., Takure, A., Nwanji, I., Farinre, O., & Adenipekun, A. (2025). EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON FASTING BLOOD GLUCOSE IN PROSTATE CANCER PATIENTS AT A TEACHING HOSPITAL IN SOUTHWESTERN NIGERIA - A PILOT STUDY. Nigerian Journal of Oncology, 1(2), 289-299. https://doi.org/10.67579/njo.2025.z2hnreiu

D. J. Obi, C. Ehiedu, A. A. Abdus-Salam, A. I. Ntekim, A. Takure, I. Nwanji, O. Farinre, and A. Adenipekun, "EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON FASTING BLOOD GLUCOSE IN PROSTATE CANCER PATIENTS AT A TEACHING HOSPITAL IN SOUTHWESTERN NIGERIA - A PILOT STUDY," Nigerian Journal of Oncology, vol. 1, no. 2, pp. 289-299, July 2025. doi: 10.67579/njo.2025.z2hnreiu

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles